Table 5. Human lymphoma and leukemia cell lines exposed to 3d and Top1, HDAC, and dual Top1/HDAC inhibitor CY700.
| Cpd | MINO | MAVER-2 | JECO-1 | U-2932 | OCI-LY3 | L-428 | KM-H2 | DG-75 | NB4 |
|---|---|---|---|---|---|---|---|---|---|
| IC50 ± SD (μM) | |||||||||
| 3d | 0.031±0.01 | 0.012±0.001 | 0.023±0.006 | 0.044±0.01 | 0.018±0.005 | 0.43±0.07 | 0.39±0.1 | 1.9±0.2 | n.e. |
| Irinotecan | >10(36%) | 0.74 ± 0.1 | >10 (48%) | 4.4 ± 0.8 | > 10 (0%) | >10(0%) | >10(12%) | >10(0%) | 1.0±0.3 |
| CY700 | 0.37± 0.1 | 0.4 ± 0.08 | 1.0 ± 0.4 | 0.9 ± 0.3 | 0.34±0.04 | 1.7 ± 0.2 | 1.5 ± 0.5 | >10(18%) | 0.24±0.06 |
| SAHA | 1.1 ± 0.3 | 5.4 ± 1.2 | 2.6 ± 0.7 | 1.1 ± 0.2 | 0.99 ± 0.3 | 2.3± 0.5 | 1.2± 0.2 | 2.1 ± 0.2 | 3.3± 0.6 |
Human hematologic cancer cells were exposed to various Top1, HDAC, and dual Top1/HDAC inhibitors and the anti-proliferative activity assessed after 72 h with the MTT assay. Ne = not evaluated.